Skip to main content

Table 2 Applied treatment options during disease progression in all patients (n = 35)

From: Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival

  Therapies prior to initial PRRT Additional therapies after initial PRRT and prior to salvage PRRT Additional therapies after salvage PRRT
Surgery 23 (65.7%) 9 (25.7%)
Biotherapy 22 (62.9%) 5 (14.3%)
Local ablative therapy (RFA, TACE, SIRT)a 12 (34.3%) 9 (25.7%) 3 (8.6%)
Chemotherapy 2 (5.7%) 1 (2.9%) 7 (20.0%)
Everolimus 1 (2.9%) 10 (28.6%)
Protein Kinase Inhibitor / Antibodyb 8 (22.9%)
Radiotherapy 2 (5.7%) 3 (8.6%) 1 (2.9%)
Bone targeted therapyc 7 (20.0%) 5 (14.3%) 4 (11.4%)
  1. aRFA Radiofrequency ablation, TACE transarterial chemoembolisation, SIRT selective internal radiotherapy; b including tyrosine kinase inhibitors and bevacizumab, c Denosumab and Bisphosphonates
\